Letter from the Editor

Dear Reader,

It is a pleasure to have been the Editor of this report on the 6^th World Psoriasis and Psoriatic Arthritis. The congress is unique as it is organised by patient associations and not by an organisation of healthcare professionals. The result is a symposium that connects the various medical specialisms and healthcare providers with different disciplines involved in psoriasis care.

In this interdisciplinary symposium, important current information on gut-skin axis, cardiovascular comorbidity and arthritis were found.

The gap between patient perception and the perception of the healthcare providers has been presented in various presentations. Important is the population study UPLIFT, which is a true representation of the general population.

Disease progression is another major item. The value of patient registries as a resource for analysing long-term data remains very important.

COVID-19 has affected psoriasis care in various dimensions: the susceptibility to contract COVID-19; the effect of anti-psoriatic treatments on the course of COVID-19; and the efficacy of vaccinations during systemic anti-inflammatory treatments.

New treatments just around the corner include bimekizumab, an anti-IL-17 AF inhibitor, spesolimab, an IL-36 inhibitor, and the TYK 2 inhibitor deucravacitinib.

This report gives you an impression of the most important messages, without the ambition to be complete.

Best Regards,

Prof. Peter CM van de Kerkhof

 

Biography

Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.

 

Copyright ©2021 Medicom Medische Uitgeverij BV



Posted on 16 September 202118 April 2023